Existing evidence suggests that targeting HIF-1α is not sufficient to disrupt the metabolism of cancer cells [47], which highlights the need for further investigation of anti-HIF-1 drugs, including their combination with other therapeutic approaches [137]. Here, HIF1A is linked to cancer.